Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Everolimus

FDA-approved product (tablet, oral), marketed as Afinitor, Afinitor Disperz, Everolimus and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Everolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Anaplastic astrocytoma
  • Angiomyolipoma
  • Astrocytoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Clear cell renal carcinoma
  • Hamartoma
  • Kidney Angiomyolipoma
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Pancreatic neuroendocrine tumor
  • and 5 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Everolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Everolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

    NCT01150097 · start 2010-03-31

    Registered record
    Registry ID
    NCT01150097
    Conditions
    Liver Transplant Recipient
    Interventions
    Tacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination); Tacrolimus (tacrolimus control); Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03-31
    Completion
    2013-05-03
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Recipient
    InterventionTacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination) +2 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

    NCT01088048 · start 2010-03-25

    Registered record
    Registry ID
    NCT01088048
    Conditions
    Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
    Interventions
    Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03-25
    Completion
    2015-04-28
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
    InterventionIdelalisib; Rituximab; Bendamustine; Ofatumumab +5 more
    PhasePhase 1
    Registry statusCompleted

  • PROMUS Element Japan Small Vessel Trial

    NCT01080261 · start 2010-02

    Registered record
    Registry ID
    NCT01080261
    Conditions
    Atherosclerosis; Coronary Artery Disease
    Interventions
    PROMUS Element
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Coronary Artery Disease
    InterventionPROMUS Element
    PhasePhase 3
    Registry statusCompleted

  • Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

    NCT00976248 · start 2009-11

    Registered record
    Registry ID
    NCT00976248
    Conditions
    Waldenstrom's Macroglobulinemia
    Interventions
    RAD001
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-11
    Completion
    2018-07
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom's Macroglobulinemia
    InterventionRAD001
    PhasePhase 2
    Registry statusCompleted

  • Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

    NCT01007942 · start 2009-10

    Registered record
    Registry ID
    NCT01007942
    Conditions
    HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventions
    everolimus; Placebo; vinorelbine; trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2015-06
    Enrolment
    569

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventioneverolimus; Placebo; vinorelbine; trastuzumab
    PhasePhase 3
    Registry statusCompleted

  • ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months

    NCT01091740 · start 2009-08

    Registered record
    Registry ID
    NCT01091740
    Conditions
    Coronary Artery Disease
    Interventions
    ZES resolute (Endeavor Resolute); EES (Xience)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionZES resolute (Endeavor Resolute); EES (Xience)
    PhasePhase 4
    Registry statusCompleted

  • COmplex BifuRcation Lesions: A Comparison Between the AXXESS Device and Culotte Stenting: An Optical Coherence Tomography (OCT) Study

    NCT00895791 · start 2009-06

    Registered record
    Registry ID
    NCT00895791
    Conditions
    Coronary Artery Stenosis
    Interventions
    AXXESS Biolimus A9-eluting bifurcation stent; culotte stenting (Xience V)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2009-06
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Stenosis
    InterventionAXXESS Biolimus A9-eluting bifurcation stent; culotte stenting (Xience V)
    PhaseNot applicable
    Registry statusWithdrawn

  • STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study

    NCT01065519 · start 2009-06

    Registered record
    Registry ID
    NCT01065519
    Conditions
    Coronary Artery Disease
    Interventions
    Xience V everolimus eluting stent; Biolimus A9-eluting Biomatrix stent
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-06
    Completion
    2016-01-14
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionXience V everolimus eluting stent; Biolimus A9-eluting Biomatrix stent
    PhaseNot applicable
    Registry statusCompleted

  • Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

    NCT01313390 · start 2009-06

    Registered record
    Registry ID
    NCT01313390
    Conditions
    Head and Neck Cancer
    Interventions
    docetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2011-04
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventiondocetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study

    NCT00828087 · start 2008-12

    Registered record
    Registry ID
    NCT00828087
    Conditions
    Myocardial Infarction
    Interventions
    Everolimus Eluting Coronary Stent System; cobalt chromium balloon expandable stent ( non drug eluting stent Arm)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-12
    Completion
    2015-05
    Enrolment
    1,504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionEverolimus Eluting Coronary Stent System; cobalt chromium balloon expandable stent ( non drug eluting stent Arm)
    PhaseNot applicable
    Registry statusCompleted

  • A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

    NCT00714025 · start 2008-11

    Registered record
    Registry ID
    NCT00714025
    Conditions
    Transitional Cell Carcinoma
    Interventions
    RAD001
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2012-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransitional Cell Carcinoma
    InterventionRAD001
    PhasePhase 2
    Registry statusCompleted

  • Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World

    NCT00768846 · start 2008-09

    Registered record
    Registry ID
    NCT00768846
    Conditions
    Coronary Artery Disease
    Interventions
    Endeavor Resolute Stent; Xience V Stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-09
    Completion
    2011-06
    Enrolment
    2,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionEndeavor Resolute Stent; Xience V Stent
    PhasePhase 4
    Registry statusUnknown

  • XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

    NCT00676520 · start 2008-07

    Registered record
    Registry ID
    NCT00676520
    Conditions
    Coronary Artery Disease
    Interventions
    XIENCE V® Everolimus Eluting Coronary Stent
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-03
    Enrolment
    8,053

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionXIENCE V® Everolimus Eluting Coronary Stent
    PhaseNot recorded
    Registry statusCompleted

  • Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

    NCT00855114 · start 2008-07

    Registered record
    Registry ID
    NCT00855114
    Conditions
    Breast Cancer
    Interventions
    everolimus; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2008-07
    Completion
    2009-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioneverolimus; therapeutic conventional surgery
    PhasePhase 2
    Registry statusWithdrawn

  • RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

    NCT00729638 · start 2008-06

    Registered record
    Registry ID
    NCT00729638
    Conditions
    Multiple Myeloma
    Interventions
    RAD001; lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionRAD001; lenalidomide
    PhasePhase 1
    Registry statusCompleted